If you read my previous post ,you will see Senator McCain’s plan to eliminate the Prostate Cancer Research Program within the Congressionally Directed Medical Research Program (CDMRP). The loss of this program could shorten many of our lives and add significantly to our pain and suffering. Now is the time to work with the rest of [...]
A new Phase 2 clinical trial of tesetaxel in men with castrate resistant advanced prostate cancer will be conducted through the Prostate Cancer Clinical Trials Consortium (PCCTC). Tesetaxel, an oral taxane which is in clinical development, will be evaluated for its use as both first- and second-line chemotherapy. […]
The Washington Post has written an article about the funding controversy surrounding the Department of Defense (DOD) Medical Research Programs. I urge everyone to go to the web site and add your comments. Members of congress do read the Washington Post daily. Please go to: The Washington Post It would be a good idea if [...]
I am in Orlando Florida attending the Department of Defense Impact Conference for the Prostate Cancer Research Program (PCRP) This DOD program is among the largest funders of prostate cancer research in the world and what is important is that the funding is designed to move research ideas that are specifically designed to have a [...]
Researchers at the Medical Oncology Unit, University of Siena, Viale Bracci 11, 53100, Siena, Italy performed a randomized phase II study which compared the activity and safety of the combination docetaxel (D)/epirubicin (EPI) with the standard of care D/prednisone (P) in men with advanced castrate-resistant prostate cancer (CRPC). […]
Light the White House Blue in September 2011 is Malecare's latest prostate cancer awareness campaign. Part petition, part people's advocacy effort, Light the White House Blue has a petition and voice of the people page at http://lightthewhitehouseblue.org Sign it, today!
Tomorrow, Wednesday- March 2, I will be joining Dr. Daniel Petrylak for a number of radio interviews about prostate cancer. Dr. Petrylak is a world renowned prostate cancer researcher and clinician. He was the principal investigator in for the development of Taxotere (docetaxel). I anticipate that we will cover a number of different prostate cancer [...]
As Black History Month comes to a close for the 35th time I am left reinvigorated. The family and I went to Washington DC last week for four days to see the sights. It's one of those things that I always wanted to do but like so many things in my childhood it was just [...]
Researchers wanted to determine if concurrent the development of morbidity issues ( i.e.- myocardial infarction, congestive heart failure, angina, diabetes, stroke, circulation problems, inflammatory bowel disease, or amputation) is associated with treatment regret among men with PSA recurrence following failed primary therapy for prostate cancer. The researchers evaluated 795 men from the Comprehensive, Observational, Multicenter, [...]
In prior studies with men who have had a PSA recurrence after radiotherapy (RT), intermittent androgen suppression (IAS) has been suggested to improve quality of life (QoL) but effects on survival are unknown. The researchers performed an inter-group randomized phase III trial, which compared IAS vs continuous androgen deprivation (CAD) to test overall survival (OS) [...]
